Anavex Life Sciences Corp (AVXL)

[nidan7500]

This is excellent news. Dr. Grimmer (as shown on previous AVXL thread) is a WW AD medical-researcher leader example (IMO) . If this presentation work reveals what I "Think it will "...then the combination of Dr. Grimmer skills, excellence of AVXL products-W/research findings will be (BOOOM) explosive WW. IMO, this helps to ensure early approvals by E U Medical leadership. BRILLINATLY DONE.


IMO, this work may (overnight) project AVXL to an CNS world leadership position. . BRILLIANT STUFF ...I PREDICT GREAT THINGS EVOLVING FROM HERE.

IMO, Dr. Grimmer presents the deep knowledge and skills of a "Systems Thinker". (see dr. Peter Senge, M.I.T. Leader)

[Saturday March 9, 2024, Just two weeks from TODAY!!!

BLARCAMESINE IN EARLY SYMPTOMATIC ALZHEIMER DISEASE PHASE 2B/3 RANDOMIZED CLINICAL TRIAL

Presenter
Timo Grimmer (Germany)
Lecture Time
09:10 - 09:25
Abstract
Aims

To assess in early Alzheimer’s disease (AD) patient’s efficacy and adverse events of blarcamesine
(ANAVEX®2-73), an orally available, small-molecule activator of the sigma-1 receptor (SIGMAR1) designed
to exert neuroprotection through restoration of cellular homeostasis.

Methods

ANAVEX®2-73-AD-004 48-week study was an international, double-blind, multicenter, placebo-controlled
Phase 2b/3 clinical study. 508 patients with AD were randomized to blarcamesine or placebo. The clinical
outcomes (primary, secondary, and exploratory) included ADAS-Cog13, ADCS-ADL, CDR-SB, and CGI-I,
which were analyzed using a mixed model for repeated measures (MMRM) and biomarkers from the A/T/N
spectrum, plasma Aß42/40 ratio and brain volume measured by MRI.

Results

The trial was successful, since the differences in the least-squares mean (LSM) change from baseline to 48
weeks between the blarcamesine and placebo groups were -1.783 [95% CI, -3.314 to -0.251]; (P = 0.0226)
for ADAS-Cog13, and -0.456 [95% CI, -0.831 to -0.080]; (P = 0.0175) for CDR-SB in patients with early AD.
In addition, validated biomarkers of amyloid beta pathology, plasma Aß42/40 ratio increased significantly (P
= 0.048), demonstrating strong anti-amyloid effects of blarcamesine in Alzheimer’s disease patients, while
MRI revealed significant reduction in brain volume loss, including whole brain (P = 0.0005), comparing
treatment to placebo.

Good luck and GOD bless,/quote]